BeijingJune 23, 2026 /PRNewswire/ — At the recently concluded 4th International Supply Chain Expo (“Chain Expo”), medical imaging innovation company Nanovision made its debut on this international stage with its phased-array CT system. Leveraging the Chain Expo’s platform effect of “Connecting the World, Creating the Future,” the company comprehensively showcased its latest industrialization achievements in the high-end medical equipment sector, further strengthening collaboration with global industry and supply chain partners to jointly drive the development and improvement of the next-generation high-end medical equipment industry ecosystem.
As a disruptive innovation in the field of medical imaging, the phased-array CT system revolutionizes the imaging model of traditional CT from its foundational architecture, widely regarded by the industry as a generational breakthrough in the evolution of CT technology. Unlike traditional CT, which relies on mechanical components for high-speed rotation to collect data, the phased-array CT innovatively employs an array of X-ray sources and detectors for electronic scanning, achieving a leap from “mechanical rotation” to “electronic scanning.” This not only captures higher-resolution, more detailed images of human tissue structures but also ensures better temporal consistency in imaging, paving a more efficient and safer path for refined disease assessment and precision medicine. Additionally, as medical imaging advances toward digitalization and intelligence, the high-density imaging data generated by phased-array CT provides a richer data foundation for the innovative application of new technologies such as artificial intelligence in the medical field.
The industrialization and widespread adoption of high-end medical equipment rely on the aggregation of global innovation elements and deep synergy within the ecosystem. The industrialization of phased-array CT involves multiple industry chain segments, including high-performance computing, advanced detectors, precision electronics, AI algorithms, high-end manufacturing, and software systems. Nanovision’s participation in this exhibition is not only a concentrated display of its innovative achievements but also a strong signal of China’s high-end medical manufacturing deeply integrating into the global industrial division of labor and promoting international cooperation.
Li Yunxiang, Founder, CEO, and President of Nanovision, stated: “Every fundamental breakthrough in medical imaging technology will have a profound impact on global public health. The Chain Expo is not just a stage for showcasing; it is a bridge connecting global innovation resources. We hope to take this opportunity to comprehensively advance the deployment and application of phased-array CT across multiple centers and scenarios worldwide, deepening collaborative innovation with global medical institutions, research organizations, and industry partners.”
During the exhibition, Nanovision fully disclosed the substantial progress in its latest industrialization and overseas market expansion. Developed by Nanovision, the world’s first phased-array CT system, “CompoundEye 24,” has officially received approval from China’s National Medical Products Administration (NMPA), becoming the first phased-array CT system globally to achieve industrial application. Currently, Nanovision is accelerating overseas registration and has submitted an application for certification under the European Union’s Medical Device Regulation (MDR) to European regulatory authorities, with the certification process progressing steadily as planned. As one of the most stringent certification systems for medical devices globally, the EU MDR regulation is a key legal basis for products to enter the EU market and obtain CE marking.
At the same time, Nanovision has signed a strategic memorandum of understanding with Genpharm, a leading regional pharmaceutical marketing and clinical solutions company headquartered in the UAE, to jointly promote the deployment and adoption of next-generation medical imaging technology architecture in the Middle East and North Africa region.
Yuan Li, Chief Operating Officer of Nanovision, noted: “The future of the medical equipment industry lies in the integration of global ecosystems. The international expansion of cutting-edge medical innovations requires not only robust technological support but also high-standard international operations and industry chain collaboration. We look forward to working hand-in-hand with research institutions, clinical hospitals, and upstream and downstream supply chain partners worldwide to advance high-level industrial cooperation, enabling China’s original high-end medical achievements to serve overseas medical institutions and global patients earlier and more safely.”
At a critical juncture in the transformation and upgrading of the global healthcare industry, ensuring the resilience and stability of supply chains and promoting equitable access to innovative technologies has become an international consensus. Nanovision will continue to adhere to a development philosophy that balances independent innovation with open cooperation, accelerating the clinical application and industrialization of phased-array CT globally. Together with global partners, the company aims to drive the development of next-generation medical imaging technology and contribute Chinese innovation to building a more inclusive, efficient, and intelligent healthcare system.
